The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 16, 2026
Snapshot (as of Oct 16, 2026): AbbVie Inc. (ABBV) pays a $6.83 annual dividend ($1.73 quarterly), yielding 2.52% at $283.40/share. Next ex-dividend date 2026-10-15. 11+ consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.52%
Annual Dividend: $6.83 per share
Payout Ratio: 190.4% (based on depressed trailing earnings — see safety analysis below)
Ex-Dividend Date: 2026-10-15
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 14
AbbVie Inc. dividend investors are looking at a biopharmaceutical company built around blockbuster therapies like Skyrizi, Rinvoq, and Botox Therapeutic, spanning autoimmune diseases, blood cancers, and neuroscience. ABBV currently pays a 2.5% dividend yield, with trailing twelve-month payments of $6.83 per share on a quarterly schedule. The next ex-dividend date is October 15, 2026, with the last declared quarterly payment at $1.73 per share. A beta of 0.228 means ABBV stock moves far less than the broader market, which appeals to income investors who prioritize low volatility over maximum yield.
AbbVie Inc. pays out 190.4% of earnings as dividends, a payout ratio classified as high (above 75%). That figure sits well above 100%, meaning current earnings alone do not cover the dividend. AbbVie Inc. dividend safety rests on the breadth of its commercial portfolio, with high-demand therapies across autoimmune, oncology, and aesthetics categories generating ongoing revenue. The most significant pressure point is that a payout ratio this elevated leaves little room to absorb an earnings decline without forcing a dividend review.
AbbVie Inc. dividend history shows a CAGR of 12.5% per year from 2013 to 2025. The per-share annual dividend grew from $1.60 to $6.56 over that window (2026 data is a partial year and excluded from the CAGR calculation). The smallest annual increase in the window was 3.7% in 2014, while the largest single-year jump reached 40.2% in 2018. Eleven consecutive years of increases confirm a pattern of uninterrupted growth, even if the pace has moderated in recent years.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +5.2% | $5.64 (2022) | $6.56 (2025) |
| 5-Year | +6.8% | $4.72 (2020) | $6.56 (2025) |
| 10-Year | +12.5% | $2.02 (2015) | $6.56 (2025) |
ABBV fits dividend investors who want a combination of meaningful income and above-average historical growth, and who can accept an elevated payout ratio as the trade-off. The current yield of 2.5% falls in the moderate (2-4%) range and sits below the 5-year average yield of 3.44%, meaning the stock is currently priced at a premium relative to its own income history. A 12.5% annual dividend CAGR over 12 years is genuinely strong for a large healthcare company, but the 190.4% payout ratio is the defining tension here. What an investor gets is a growing dividend backed by a diversified drug portfolio. What they accept is a payout structure that depends on earnings recovery to remain self-sustaining.
| Payment Date | Amount per Share |
|---|---|
| 2026-10-15 | $1.7300 |
| 2026-07-15 | $1.7300 |
| 2026-04-15 | $1.7300 |
| 2026-01-16 | $1.7300 |
| 2025-10-15 | $1.6400 |
| 2025-07-15 | $1.6400 |
| 2025-04-15 | $1.6400 |
| 2025-01-15 | $1.6400 |
| 2024-10-15 | $1.5500 |
| 2024-07-15 | $1.5500 |
| Year | Total Dividends |
|---|---|
| 2026 | $6.9200 |
| 2025 | $6.5600 |
| 2024 | $6.2000 |
| 2023 | $5.9200 |
| 2022 | $5.6400 |
Project income from ABBV with the ABBV dividend calculator or track your full portfolio with the dividend tracker.